OSTX

OS Therapies Incorporated

0.89

USD

-0.03

-3.27%

Nov 10, 15:59 UTC -5

Closed

After-Market

0.90

+0.01

+1.01%

OS Therapies Incorporated (OSTX) Earnings

OSTX Earnings Reports

Positive Surprise Ratio

OSTX beat 1 of 8 last estimates.

13%

Next Report

In 3 Days

Date of Next Report

Nov 13, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.14

Implied change from Q2 26 (Revenue/ EPS)

-30.00%

Implied change from Q3 25 (Revenue/ EPS)

-33.33%

OS Therapies Incorporated earnings per share and revenue

On Aug 14, 2026, OSTX reported earnings of -0.20 USD per share (EPS) for Q2 26, beating the estimate of -0.21 USD, resulting in a 4.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -9.26% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -30.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

CalciMedica, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.30

Actual

-$0.72

Surprise

+44.64%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

FAQ

What were OS Therapies Incorporated's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, OS Therapies Incorporated reported EPS of -$0.20, beating estimates by 4.81%, and revenue of $0.00, 0% as expectations.

How did the market react to OS Therapies Incorporated's Q2 2026 earnings?

The stock price moved down -9.26%, changed from $1.62 before the earnings release to $1.47 the day after.

When is OS Therapies Incorporated expected to report next?

The next earning report is scheduled for Nov 13, 2026.

What are the forecasts for OS Therapies Incorporated's next earnings report?

Based on -- analysts, OS Therapies Incorporated is expected to report EPS of -$0.14 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.